Defying recent prophecies of doom for proteomics service companies, both Oxford GlycoSciences and MDS Proteomics announced new research partnerships last week that will provide them with fresh revenues and bring OGS closer to its stated goal of leading its proteomics division to profitability this year.

While OGS reached a new agreement with its longstanding partner Pfizer, MDSP signed a five-year contract with biotechnology company Cephalon.